While it has been demonstrated that inhibiting CSF1R via PLX3397 (pexidartinib)204 has antitumor effects in adult T-cell leukemia/lymphoma (ATLL) by inducing ATL-T cells to undergo apoptosis and reducing the expression of PD-L1/L2205, another study shows that PLX3397 induces pancreatic ductal adenocarcinoma by upregulating T-cell checkpoint molecules206. This evidence concerns the gene CSF1R and adult T-cell leukemia/lymphoma.